Treatment and Prognosis of AIDS-Related Lymphoma in the Era of Highly Active Antiretroviral Therapy: Findings from the Swiss HIV Cohort Study

HIV infection has been associated with an increased risk of developing several types of malignancies, including aggressive peripheral T‐cell lymphomas (PTCL). However, this is a rare occurrence with no more than a hundred cases reported in the literature. The purpose of this multicenter study is to describe the characteristics and to identify prognostic factors in patients with HIV‐associated PTCL. Data from HIV‐positive patients with a pathological diagnosis of non‐primary cutaneous, non‐leukemic PTCL were gathered retrospectively and are reported using descriptive statistics. Univariate and multivariate survival analyses were also performed. Fifty one patients were included in our analysis. Median age was 38 years with a 5:1 male‐to‐female ratio. Patients presented with a median CD4+ count of 173 cells mm−3, and a median HIV viral load of 334,787 copies ml−1. The median time from HIV diagnosis to PTCL diagnosis was 4.5 years. About 75% of patients presented with advanced clinical stage and 66% with B symptoms. The most common subtypes were PTCLU (61%) and anaplastic large cell lymphoma (ALCL, 22%). None of the ALCL patients tested expressed ALK. The median overall survival (OS) for the group was 12 months. In the multivariate survival analysis, the use of HAART and patients' performance status were independently associated with OS. HIV‐associated PTCL presents predominantly in young men with low CD4+ counts and high HIV viral loads. Both HIV‐related and lymphoma‐related factors were associated with OS. Am. J. Hematol. 2011. © 2011 Wiley‐Liss, Inc.

show abstract

Population‐based outcome analysis of diffuse large B‐cell lymphoma in people living with HIV infection and competent individuals

Conconi

Zucca

Margiotta‐Casaluci

et al. 2018

Hematological Oncology

Self Cite

View full text Add to dashboard Cite

The prognostic factors and outcome of 58 acquired immunodeficiency syndrome-related diffuse large B-cell lymphoma (AR-DLBCL) patients from the Swiss HIV Cohort Study, diagnosed from 2004 to 2011, were compared with those of 326 immunocompetent (IC)-DLBCL from the Hematology Division of the Amedeo Avogadro University (Italy) and the Oncology Institute of Southern Switzerland. Median follow-up was 6 years; 5-year overall survival (OS) was 68% (95% CI: 63%-73%) in IC-DLBCL and 63% (95% CI: 49%-75%) in AR-DLBCL (P = .220). The acquired immunodeficiency syndrome-related lymphoma international prognostic index predicted OS in AR-DLBCL. Among 148 patients younger than 61 years (40 AR-DLBCL and 108 IC-DLBCL) treated with RCHOP/RCHOP-like regimens, 20 IC-DLBCL and 9 AR-DLBCL patients died and OS was not significantly different. A higher proportion of early deaths occurred in the AR-DLBCL: indeed, 1-year OS was 94% (95% CI: 87%-97%) in IC-DLBCL and 82% (95% CI: 66%-91%) in AR-DLBCL patients. After rituximab and active antiretroviral therapy introduction, AR-DLBCL and IC-DLBCL patients treated with curative intent have similar long-term survival.

show abstract

Treatment and Prognosis of AIDS-Related Lymphoma in the Era of Highly Active Antiretroviral Therapy: Findings from the Swiss HIV Cohort Study

Cited by 27 publications

References 36 publications

Interventions for previously untreated patients with AIDS-associated Non-Hodgkin´s Lymphoma

Interventions for previously untreated patients with AIDS-associated Non-Hodgkin´s Lymphoma

Prognostic factors in patients with HIV‐associated peripheral T‐cell lymphoma: A multicenter study

Population‐based outcome analysis of diffuse large B‐cell lymphoma in people living with HIV infection and competent individuals

Contact Info

Product

Resources

About